Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 69 publications.

Yan S, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Wilson M. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States. J Med Econ. 2024 May 6;27(1):758-65. doi: 10.1080/13696998.2024.2351762

Brodtkorb TH, Knight C, Kamgar F, Teitsson S, Kurt M, Patel MY, Poretta T, Mamtani R, Palmer S. Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective1. J Med Econ. 2024 Apr 4;27(1):543-53. doi: 10.1080/13696998.2024.2329019

Craig T, Baptist A, Anderson J, Zaragoza-Urdaz R, Burnette A, Kelbel T, Riedl M, Vanegas A, Boyle K, Schultz B, Blair C, Sing K, Fox D, Juethner S. Patient-reported outcomes among patients with hereditary angioedema within underrepresented racial or ethnic groups. Poster presented at the 2024 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting; February 23, 2024. Washington, DC. [abstract] J Allergy Clin Immunol. 2024 Feb; 153(2):AB81.

Dolin P, Kielar D, Shavit A, Koegh K, Rowell J, Edmonds C, Meyers J, Esterberg E, Nham T, Chen S. Comorbidities in patients with eosinophilic granulomatosis with polyangiitis versus severe uncontrolled asthma: a retrospective analysis of US health insurance claims data. Poster presented at the 2024 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting; February 23, 2024. Washington, DC. [abstract] J Allergy Clin Immunol. 2024 Feb; 153(2):AB53.

Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen S. Healthcare resource utilization and costs in patients with eosinophilic granulomatosis with polyangiitis versus severe uncontrolled asthma: a retrospective analysis of US health insurance claims data. Poster presented at the 2024 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting; February 25, 2024. Washington, DC. [abstract] J Allergy Clin Immunol. 2024 Feb; 153(2):AB206.

Teittson S, Brodtkorb T-H, Kurt M, Patel M, Poretta T, Knight C, Kamgar F, Palmer S. Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo. J Med Econ. 2024 Jan;27(1):473-81. doi: 10.1080/13696998.2024.2322394

Spelman T, Herring WL, Acosta C, Hyde R, Jokubaitis VG, Pucci E, Lugaresi A, Laureys G, Havrdova EK, Horakova D, Eichau S, Ozakbas S, Alroughani R, Kalincik T, Duquette P, Girard M, Petersen T, Patti F, Csepany T, Granella F, Grand'Maison F, Ferraro D, Karabudak R, Jose Sa M, Trojano M, Van Pesch V, Van Mijmeersch B, Cartechini E, McCombe P, Gerlach O, Spitaleri D, Rozsa C, Hodgkinson S, Bergamaschi R, Gouider R, Soysal A, Castillo-Trivino T, Prevost J, Garber J, de Gans K, Ampapa R, Simo M, Sanchez-Menoyo JL, Iuliano G, Sas A, van der Walt A, John N, Gray O, Hughes S, De Luca G, Izquierdo G, Onofrj M, Buzzard K, Skibina O, Terzi M, Slee M, Solaro C, Oreja-Guevara C, Ramo-Tello C, Fragoso Y, Shaygannejad V, Moore F, Rajda C, Aguera Morales E, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. J Med Econ. 2023 Dec;27(1):109-25. doi: 10.1080/13696998.2023.2293379

Grace M, Colosia A, Wolowacz S, Panozzo C, Ghaswalla P. Economic burden of respiratory syncytial virus infection in adults: a systematic literature review. J Med Econ. 2023;26(1):742-59. doi: 10.1080/13696998.2023.2213125

Graham CN, Watson C, Barlev A, Stevenson M, Dharnidharka VT. Mean lifetime survival estimates following solid organ transplantation in the US and UK. J Med Econ. 2022 Jan;25(1):230-7. doi: 10.1080/13696998.2022.2033050

Mladsi D, Hess LM, Barnett CL, Njue A, Huang YJ, Cui ZL, Bowman L. Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study. J Med Econ. 2020 Mar;23(3):213-20. doi: 10.1080/13696998.2019.1678479

Burte E, Leynaert B, Marcon A, Bousquet J, Benmerad M, Bono R, Carsin AE, de Hoogh K, Forsberg B, Gormand F, Heinrich J, Just J, Nieuwenhuijsen M, Pin I, Stempfelet M, Sunyer J, Villani S, Kunzli N, Siroux V, Jarvis D, Nadif R, Jacquemin B. Long-term air pollution exposure is associated with increased severity of rhinitis in 2 European cohorts. J Allergy Clin Immunol. 2020 Mar;145(3):834-842.e. doi: 10.1016/j.jaci.2019.11.040

Trantham L, Sikirica MV, Candrilli S, Benson VS, Mohan D, Neil D, Joshi AV. Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis. J Med Econ. 2019 Apr;22(4):319-27. doi: 10.1080/13696998.2018.1563414.

Meckley L, Coles T, Williams N, DiBenedetti D, McLeod L. Experience with immunoglobulin treatment among patients with PIDD in the US. Poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting; February 22, 2019. San Francisco, CA. [abstract] J Allergy Clin Immunol. 2019 Feb; 143(2 Supplement):AB112. doi: 10.1016/j.jaci.2018.12.341

Nguyen AM, Muccino D, Birring S, Bacci ED, Vernon MK, Mines D, Smith JA. Defining minimal clinically important differences (MCID) in chronic cough: analyses of objective cough counts from a phase 2 randomized controlled trial. Poster presented at the 2019 Annual Meeting of the American Academy of Asthma, Allergy and Immunology; February 2019. [abstract] J Allergy Clin Immunol. 2019 Feb; 143(2 Supplement):AB169. doi: 10.1016/j.jaci.2018.12.519

Graham CN, Christodoulopoulou A, Knox HN, Sabatelli L, Hechmati G, Garawin T, Strickler JH. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. J Med Econ. 2018 Nov;21(11):1075-83. doi: 10.1080/13696998.2018.1510409.

Igarashi A, Igarashi AS, Graham CN, Gilloteau I, Tani Y. Evaluating the cost-effectiveness of secukinumab in moderate to severe psoriasis: a Japanese perspective. J Med Econ. 2018 Oct 26;22(1):7-15. doi: 10.1080/13696998.2018.1532905.

Barnett CL, Mladsi D, Vredenburg M, Aggarwal K. Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures. J Med Econ. 2018 Aug;21(8):827-34. doi: 10.1080/13696998.2018.1490301

Guerra S, Melen E, Sunyer J, Xu CJ, Lavi I, Benet M, Bustamante M, Carsin AE, Dobano C, Guxens M, Tischer C, Vrijheid M, Kull I, Bergstrom A, Kumar A, Soderhall C, Gehring U, Dijkstra D, van der Vlies P, Wickman M, Bousquet J, Postma DS, Anto JM, Koppelman GH. Genetic and epigenetic regulation of YKL-40 in childhood. J Allergy Clin Immunol. 2018 Mar;141(3):1105-14. doi: 10.1016/j.jaci.2017.06.030

Devercelli G, Davis K, Brown M, Hollis K, Hunter S, Long J, Jain G, Banerji A. Burden of hereditary angioedema: findings from a US patient survey. Poster presented at the 2018 AAAAI/WAO Joint Congress; March 3, 2018. Orlando, FL. [abstract] J Allergy Clin Immunol. 2018 Feb; 141(2 Suppl):AB57. doi: 10.1016/j.jaci.2017.12.182

Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM, Gladman DD. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. J Med Econ. 2018 Feb;21(2):163-73. doi: 10.1080/13696998

Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, Eisner MD, Chen H, Omachi TA, Farkouh ME, Rothman KJ. Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study of moderate-to-severe asthma. J Allergy Clin Immunol. 2017 May;139(5):1489-1495. doi: 10.1016/j.jaci.2016.07.038.

Iribarren C, Rothman KJ, Bradley MS, Carrigan G, Eisner MD, Chen H. Cardiovascular and cerebrovascular events among patients receiving omalizumab: pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials. J Allergy Clin Immunol. 2017 May;139(5):1678-80. doi: 10.1016/j.jaci.2016.12.953

Rouse M, Twiss J, McKenna SP. Co-calibrating quality-of-life scores from three pulmonary disorders: implications for comparative-effectiveness research. J Med Econ. 2016 Jun;19(6):596-603. doi: 10.3111/13696998.2016.1148700

White MV, Silvia S, Hollis K, Wooddell M, Goss D, Odom D, Cooney D, Bartsch J, Hogue S. EPIPEN4SCHOOLS® survey combined analysis: prevalence and triggers of anaphylactic events. Poster presented at the 2016 AAAAI Annual Meeting; March 4, 2016. Los Angeles, CA. [abstract] J Allergy Clin Immunol. 2016; 137:AB52.

Bateman ED, Esser D, Chirila C, Fernandez M, Fowler A, Moroni-Zentgraf P, FitzGerald JM. Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: systematic review and network meta-analysis. J Allergy Clin Immunol. 2015 Oct;136(4):914-22. doi: 10.1016/j.jaci.2015.03.023

Graham CN, Hechmati G, Fakih MG, Knox HN, Maglinte GA, Hjelmgren J, Barber B, Schwartzberg LS. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. J Med Econ. 2015 Aug;18(8):619-28.

Wooddell M, Goss DS, Hollis KA, Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Hogue SL, White MV. Epinephrine administration for cases of anaphylaxis in a US school setting: results from the EpiPen4Schools survey. Poster presented at the 2015 AAAAI Annual Meeting; February 20, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015 Feb; 135(2):AB212.

Gascon M, Casas M, Morales E, Valvi D, Ballesteros-Gomez A, Luque N, Rubio S, Monfort N, Ventura R, Martinez D, Sunyer J, Vrijheid M. Prenatal exposure to bisphenol A and phthalates and childhood respiratory tract infections and allergy. J Allergy Clin Immunol. 2015 Feb;135(2):370-8. doi: 10.1016/j.jaci.2014.09.030

White MV, Goss D, Hollis K, Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Wooddell M, Hogue S. EpiPen4Schools® survey: characteristics of anaphylaxis and common triggers. Poster presented at the 2015 AAAAI Annual Meeting; February 15, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015 Feb; 135(Suppl 2):AB212.

Hogue SL, Bennett ME, Goss DS, Hollis KA, Millar K, Silvia S, Siegel P, Wolf RA, Wooddell M, White MV. Occurrence of anaphylaxis by school grade level and staff training: findings from the EpiPen4Schools survey. Poster presented at the 2015 AAAAI Annual Meeting; February 23, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015; 135(2):AB212.

White MV, Goss DS, Hollis KA, Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Wooddell M, Hogue SL. EpiPen4Schools survey: characteristics of anaphylaxis and common triggers. Poster presented at the 2015 AAAAI Annual Meeting; February 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015; 135:AB212.

Borker R. Costs associated with adverse events in patients with metastatic renal cell carcinoma. J Med Econ. 2014 Nov;17(11):792-7. doi: 10.3111/13696998.2014.945645

Brennan VK, Colosia AD, Copley-Merriman K, Mauskopf J, Haas B, Psalencia R. Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modeling. J Med Econ. 2014 Jul;17(7):469-80. doi: 10.3111/13696998.2014.915847

Stanford RS, Nagar SP, Lin X, O'Conner R. Impact of change in inhaled corticosteroids/long-acting beta agonist combination (ICS/LABA) use on the risk of asthma exacerbations in asthma patients within a medical group. Poster presented at the 2014 AAAAI Annual Meeting; February 2014. San Diego, CA. [abstract] J Allergy Clin Immunol. 2014 Feb; 133(2):AB7.

Stalhammar J, Stern L, Linder R, Sherman S, Parikh RC, Ariely R, Deschaseaux C, Wikstrom G. The burden of preserved ejection fraction heart failure in a real-world Swedish patient population. J Med Econ. 2014 Jan 25;17(1):43-51. doi: 10.3111/13696998.2013.848808

Pearson I, Rycroft C, Irving A, Ainsworth C, Wittrup-Jensen K. A systematic literature review of utility weights in wet age-related macular degeneration. J Med Econ. 2013 Nov;16(11):1307-16.

Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ. 2013 Mar 4;16(6):720-35.

Myers RA, Himes BE, Gignoux CR, Yang JJ, Gauderman WJ, Rebordosa C. Further replication studies of the eve consortium meta-analysis identifies 2 asthma risk loci in European Americans. J Allergy Clin Immunol. 2012 Dec;130(6):1294-301.

Stalhammar J, Stern L, Linder R, Sherman S, Parikh RC, Ariely R, Wikstrom G. Resource utilization and cost of heart failure associated with reduced ejection fraction in Swedish patients. J Med Econ. 2012 May;15(5):938-46.

Prazma CM, Prillaman BA, Gern JE, Stempel DA. Seasonal asthma exacerbation and viral association in a pediatric population receiving ICS ± LABA therapy. Poster presented at The 2012 AAAAI Annual Meeting; March 2, 2012. Orlando, FL. [abstract] J Allergy Clin Immunol. 2012 Feb 1; 129(2 Supplement):AB164. doi: 10.1016/j.jaci.2011.12.377

Mauskopf JA, Graham JB, Bae JP, Ramaswamy K, Zagar AJ, Magnuson EA, Cohen DJ, Meadows ES. Cost-effectiveness of prasugrel in a US managed care population. J Med Econ. 2012 Jan 1;15(1):166-74.

Sansgiry SS, Joish VN, Boklage S, Goyal RK, Chopra P, Sethi S. Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Med Econ. 2012;15(2):219-24. doi: 10.3111/13696998.2011.638954

Twiss J, McKenna SP, Crawford SR, Tammaru M, Oprandi NC. Adapting the Asthma Life Impact Scale (ALIS) for use in Southern European (Italian) and Eastern European (Russian) cultures. J Med Econ. 2011;14(6):729-38. doi: 10.3111/13696998.2011.615356

Gutierrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Robbins S, Gitlin M. Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom. J Med Econ. 2011 Jan 1;14(1):99-107.

Mauskopf JA, Baker CL, Monz BU, Juniper MD. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. J Med Econ. 2010 Sep 1;13(3):403-17.

Woodward TC, Brown R, Sacco P, Zhang J. Budget impact model of tobramycin inhalation solution for treatment of pseudomonas aeruginosa in cystic fibrosis patients. J Med Econ. 2010;13(3):492-9. doi: 10.3111/13696998.2010.505863

Zock JP, Plana E, Anto JM, Benke G, Blanc PD, Carosso A. Domestic use of hypochlorite bleach, atopic sensitization, and respiratory symptoms in adults. J Allergy Clin Immunol. 2009 Oct;124(4):731-738 e.

Mauskopf JA, Boye KS, Schmitt C, McCollam P, Birt J, Juniper MD, Bakhai A. Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy. J Med Econ. 2009 Jan 1;12(2):141-53.

Martin BG, Andrews CP, Jacobs R, Mohar D, Toler WT, Prillaman BA, Philpot EE. Once-daily fluticasone furoate nasal spray showed greater improvements in relieving nighttime nasal symptoms and increasing peak nasal inspiratory flow versus oral fexofenadine in subjects with Seasonal Allergic Rhinitis (SAR). Poster presented at the AAAI Annual Meeting; March 14, 2008. Philadelphia, PA. [abstract] J Allergy Clin Immunol. 2008 Feb 1; 121(2 Supplement 1):s54-5. doi: 10.1016/j.jaci.2007.12.220

Andrews CP, Martin BG, Jacobs RL, Toler WT, Prillaman BA, Dalal AA, Philpot EE. Once-daily fluticasone furoate nasal spray showed greater improvement in nocturnal quality of life in subjects with seasonal allergic rhinitis compared with oral fexofenadine. Poster presented at the AAAI Annual Meeting; March 14, 2008. Philadelphia, PA. [abstract] J Allergy Clin Immunol. 2008 Feb 1; 121(2 Suppl 1):s53. doi: 10.1016/j.jaci.2007.12.216